Franklin M. Berger
Independent DirectorMr. Franklin M. Berger, C.F.A., BA, MA, MBA., is Independent Director of Retension Pharmaceuticals, Inc. from December 2025. Mr. Berger has M.A. in International Economics, International Relations from Paul H Nitze School of Advanced International Studies in 1971. serves as Director of MindRhythm, Inc. since 2025. He serves as Independent Director of Satellos Bioscience Inc. since June 29, 2023. He has been a Director at Rain Oncology Inc. (formerly known as Rain Therapeutics Inc.) from May 2020 and serves as its Lead Independent Director. He serves as Director at Walking Fish Therapeutics, Inc. He serves as a Senior Advisor at Qiming Venture Partners USA. He joined Qiming US in 2019, following a career in healthcare equity research, portfolio management and strategic consulting. He has been funding and supporting early-stage biotech companies and serving on public and private boards. He served as Director of Five Prime Therapeutics, Inc. since September 2010 until April 16, 2021. Mr. Berger serves as Lead Independent Director of Atea Pharmaceuticals, Inc. since September 2019 and has been its Director since September 2019. He served as an Independent Director at BELLUS Health Inc. from May 2010 to June 2023. He is the Founder of FMR Research Inc. and serves as its Principal. Mr. Berger is the Founder and Managing Director of FMB Research since June 2005. He serves as Member of Scientific Advisory Board at Umoja BioPharma, Inc since 2025 and also served as Member of Advisory Board until 2025. Mr. Berger served as a Director of Applied Therapeutics Inc. since 2019 until May 2019. He has been a Consultant to biotechnology industry participants, including major biopharmaceutical firms, mid-capitalization biotechnology companies, specialist asset Managers and venture capital companies, providing business development, strategic, financing, Partnering and royalty acquisition advice since 2003. Mr. Berger is also a biotechnology industry Analyst with experience in capital markets and financial analysis. He had been Independent Director of Atreca, Inc. since October 2014, until June 2024. He served as the Managing Director of U.S. of Equity Research at J.P. Morgan Securities Inc. from May 1998 to March 2003 and Senior Biotechnology Analyst at J.P. Morgan Securities LLC from 1998 to 2003. While he was at the J.P. Morgan Securities Inc., his Research Group Maintained Coverage of 26 Biotechnology Companies; he had Primary Responsibility for Technical, Scientific and Clinical Due Diligence as well as selection of biotechnology companies followed by J.P. Morgan. He was associated with several notable financings in the biotechnology sector including the Genentech IPO, the largest biotechnology financing ever executed & the first large Celgene Corporation financings as well as financings of several large-cap companies in their rapid growth phase. From May 2007 to June 2008, Mr. Berger served as a Senior Investment Manager and Senior Portfolio Manager of Sectoral Asset Management, Inc., where he was Founder of the NEMO Fund from January 2007 through June 2008. He served as an Independent Director of Kezar Life Sciences, Inc. since January 2016 until May 11, 2026. He served as a Director of Equity Research and Senior Biotechnology Analyst for Salomon Smith Barney. He served as Equity Analyst of Salomon Brothers Inc., Research Division. Previously, he served positions at Salomon Smith Barney from 1997 to 1998 and Josephthal & Co. from 1991 to 1997. He served as Analyst of Josephthal & Co., Inc., Research Division and Josephthal & Co., Inc. Prior to his work as a biotechnology Analyst, he managed Pantagruel Partners as an Investment Professional. He served as Research Analyst of JP Morgan Chase & Co, Research Division and Equity Analyst of Citigroup Inc., Research Division. He served as Director of Equity Research at Citigroup CIB. Mr. Berger serves as a Director of iTherX, Inc. (itherX Pharmaceuticals, Inc). He served as Director of Immune Design Corp. since March 18, 2014 until June 2019. He served as Independent Director of ESSA Pharma Inc. since March 15, 2015 until October 09, 2025. He serves as a Lead Independent Director of Thallion Pharmaceuticals, Inc. and has been its Director since March 2007. He served as a Member of the External Advisory Board at Valeant Pharmaceuticals International, Inc. (formerly, Biovail Corporation) since March 2009. He served as a Director of Asterias Biotherapeutics, Inc. from June 2013 to March 21, 2014. He served as a Director of Tocagen Inc. from October 2014 to June 2020. He served as a Director of ViroChem Pharma, Inc. and Caprion Proteomics, Inc. Mr. Berger served as a Director of VaxGen Inc. from December 2, 2003 to July 28, 2010 and Seattle Genetics, Inc. from June 2004 to May 16, 2014. He served as a Director of Emisphere Technologies, Inc., from May 19, 2009 to October 23, 2009. He served as a Director of Alzheon, Inc. since January 2014. He served as a Director of BioTime, Inc. from May 14, 2013 to March 2014. He served as a Director of diaDexus, Inc. until July 28, 2010. He served as a Director of HealthShares (TM) Inc. - HealthShares Patient Care Services Index Exchange Traded Fund (formerly, HealthShares Patient Care Services Exchange-Traded Fund). Mr. Berger previously served as a Member of the Board of Directors of Proteostasis Therapeutics, Incorporated from February 2016 to December 2020. Mr. Berger served as a Director of Aurinia Pharmaceuticals Inc. (Isotechnika Pharma Inc.) from February 22, 2006 to February 2011. In 2002, Institutional Investor Magazine ranked him in 3rd-place on its All-Star Research Team for biotechnology. The Wall Street Journal 2000 ranked Mr. Berger as the number 1 biotechnology Analyst in its All-Star Analyst Survey in 1997 and ranked him number 2 in the 2000 Survey. In 2000, he became a Founding Fellow of the Biotechnology Study Center at New York University School of Medicine. Mr. Berger earned his B.A. in International Relations from Johns Hopkins University in 1972 and M.A. in International Economics from Johns Hopkins University for School for Advanced International Studies in 1971 and his M.B.A. from the Harvard University in 1975 and CFA from AIMR.
Positions
- Company NameRetension Pharmaceuticals, Inc.Stock CodeRTSNPositionIndependent DirectorColleagues
- MJMichael Joseph BerendtExecutive Chairman
- EKEric KellerCo-founder, CEO & Director
- PSPaul SweetnamCo-Founder, Chief Scientific Officer & Secretary
- ADAlexander Duke SchwartzChief Financial Officer
- SBSabine BissonChief Operations Officer
- DJDonald John OldsIndependent Director
- OAOmar Al DhaybiMember of Scientific Advisory Board
- Company NameAtea Pharmaceuticals, Inc.Stock CodeAVIRPositionLead Independent DirectorColleagues
- JSJean-Pierre SommadossiFounder, Chairman, CEO & President
- AJAndrea J. CorcoranCFO, Executive VP of Legal & Secretary
- JFJohn F. VavrickaChief Commercial Officer
- JMJanet M. J. HammondChief Development Officer
- MAMaria Arantxa HorgaChief Medical Officer
- FMFranklin M. BergerLead Independent Director
- PAPolly A. MurphyIndependent Director
- BGBarbara G. DuncanIndependent Director
- BLBruno LucidiIndependent Director
